{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:59Z","timestamp":1740144059762,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:00:00Z","timestamp":1590796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:00:00Z","timestamp":1590796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Government-wide R&D Fund for Infectious Disease Research","award":["HG18C0068"],"award-info":[{"award-number":["HG18C0068"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40261-020-00930-6","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T09:02:44Z","timestamp":1590829364000},"page":"727-735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-approval Safety Monitoring of Quadrivalent and Bivalent Human Papillomavirus Vaccines Based on Real-world Data from the Korea Adverse Events Reporting System (KAERS)"],"prefix":"10.1007","volume":"40","author":[{"given":"MoonJung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SangHee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-7525","authenticated-orcid":false,"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,30]]},"reference":[{"key":"930_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.5124\/jkma.2007.50.9.762","volume":"50","author":"KW Lee","year":"2007","unstructured":"Lee KW, Song JY. Epidemiology of cervical cancer. J Korean Med Assoc. 2007;50:762\u20138.","journal-title":"J Korean Med Assoc."},{"key":"930_CR2","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.vaccine.2005.01.016","volume":"23","author":"EL Franco","year":"2005","unstructured":"Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine. 2005;23:2388\u201394.","journal-title":"Vaccine."},{"key":"930_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.5124\/jkma.2015.58.4.313","volume":"58","author":"B-G Kim","year":"2015","unstructured":"Kim B-G. Update of human papillomavirus vaccination. J Korean Med Assoc. 2015;58:313\u20138.","journal-title":"J Korean Med Assoc."},{"key":"930_CR4","first-page":"2","volume":"1","author":"KP Braaten","year":"2008","unstructured":"Braaten KP, Laufer MR. Human Papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol. 2008;1:2\u201310.","journal-title":"Rev Obstet Gynecol."},{"key":"930_CR5","doi-asserted-by":"crossref","unstructured":"Lee L-Y, Garland SM. Human papillomavirus vaccination: the population impact. F1000Res. 2017;6:866.","DOI":"10.12688\/f1000research.10691.1"},{"key":"930_CR6","unstructured":"Korea Centers for Disease Control & Prevention (KCDC). HPV vaccines prevent cervical cancer. Press Release on Dec 27, 2018. https:\/\/nip.cdc.go.kr\/irgd\/support.do?service=getNewsView&strNum=246&PROSEQNUM=421&SEARCHTYPE=&SEARCHWARD. Accessed Nov 22, 2019."},{"key":"930_CR7","unstructured":"Health Insurance Statistical Yearbook data from 2014 to 2018. Health Insurance Review and Assessment Service (HIRA). 2019. https:\/\/www.hira.or.kr\/bbsDummy.do?pgmid=HIRAA020045010000&brdScnBltNo=4&brdBltNo=2319. Accessed Nov 22, 2019."},{"key":"930_CR8","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1016\/S0140-6736(15)61152-7","volume":"385","author":"SJB Hanley","year":"2015","unstructured":"Hanley SJB, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. Lancet. 2015;385:2571.","journal-title":"Lancet."},{"key":"930_CR9","unstructured":"Dennis N. Journal retracts paper claiming neurological damage from HPV vaccine. American Association for the Advancement of Science May 11, 2018. https:\/\/www.sciencemag.org\/news\/2018\/05\/journal-retracts-paper-claiming-neurological-damage-hpv-vaccine. Accessed Nov 22, 2019."},{"key":"930_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.phrs.2018.04.007","volume":"132","author":"M Julie","year":"2018","unstructured":"Julie M, Francesco S, Emanuel R, Elisabetta P, Ippazio CA, Fabrizio DP, et al. Human papillomavirus vaccine and demyelinating diseases\u2013a systematic review and meta-analysis. Pharmacol Res. 2018;132:108\u201318.","journal-title":"Pharmacol Res."},{"key":"930_CR11","unstructured":"World Health Organization. Safety update of HPV vaccines. Extract from report of GACVS meeting of 7\u20138 June 2017. 2017. http:\/\/www.who.int\/vaccine_safety\/committee\/topics\/hpv\/June_2017\/en\/. Accessed Nov 22, 2019."},{"key":"930_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.4161\/hv.5.10.9518","volume":"5","author":"MH Einstein","year":"2009","unstructured":"Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18\u201345 years. Hum Vaccin. 2009;5:705\u201319.","journal-title":"Hum Vaccin."},{"key":"930_CR13","doi-asserted-by":"publisher","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","volume":"30","author":"JT Schiller","year":"2012","unstructured":"Schiller JT, Castellsagu\u00e9 X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30:F123\u201338.","journal-title":"Vaccine."},{"key":"930_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2334-11-13","volume":"11","author":"B Lu","year":"2011","unstructured":"Lu B, Kumar A, Castellsagu\u00e9 X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 2011;11:13.","journal-title":"BMC Infect Dis."},{"key":"930_CR15","doi-asserted-by":"publisher","first-page":"6630","DOI":"10.1016\/j.vaccine.2008.09.049","volume":"26","author":"T Verstraeten","year":"2008","unstructured":"Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 2008;26:6630\u20138.","journal-title":"Vaccine."},{"key":"930_CR16","unstructured":"EJ Kim. A report of National Assembly Legislative Survey. Improvement plan of adverse event reporting system. December 19. 2019. https:\/\/www.assembly.go.kr\/assm\/notification\/news\/news01\/bodo\/bodoView.do?bbs_id=ANCPUBINFO_05&bbs_num=47949&no=6482. Accessed Dec 27, 2019."},{"key":"930_CR17","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.4161\/hv.34408","volume":"10","author":"DM Herrin","year":"2014","unstructured":"Herrin DM, Coates EE, Costner PJ, Kemp TJ, Nason MC, Saharia KK, et al. Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus. Hum Vaccin Immunother. 2014;10:3446\u201354.","journal-title":"Hum Vaccin Immunother."},{"key":"930_CR18","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/infdis\/jit657","volume":"209","author":"L Toft","year":"2013","unstructured":"Toft L, Storgaard M, M\u00fcller M, Sehr P, Bonde J, Tolstrup M, et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis. 2013;209:1165\u201373.","journal-title":"J Infect Dis."},{"key":"930_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.4161\/hv.5.5.7211","volume":"5","author":"D Descamps","year":"2009","unstructured":"Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, et al. Safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009;5:332\u201340.","journal-title":"Hum Vaccin."},{"issue":"697\u2013712","key":"930_CR20","first-page":"21","volume":"14","author":"S Michela","year":"2015","unstructured":"Michela S, Paloma CS, Pier LL. Safety of human papillomavirus vaccines: a review. Expert Opin. Drug Saf. 2015;14(697\u2013712):21.","journal-title":"Expert Opin. Drug Saf."},{"key":"930_CR21","first-page":"2","volume":"12","author":"L Tomljenovic","year":"2012","unstructured":"Tomljenovic L, Shaw CA. Death after quadrivalent human papillomavirus (HPV) vaccination: causal or coincidental. Pharmaceut Reg Affairs S. 2012;12:2.","journal-title":"Pharmaceut Reg Affairs S."},{"key":"930_CR22","doi-asserted-by":"crossref","unstructured":"Reddy N, Subeesh KV, Beulah T. Postlicensure surveillance of human papillomavirus vaccine using the Vaccine Adverse Event Reporting System, 2006\u20132017. Perspect Clin Res 2020;11:24\u201330","DOI":"10.4103\/picr.PICR_140_18"},{"key":"930_CR23","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.vaccine.2018.02.034","volume":"36","author":"JE Arana","year":"2018","unstructured":"Arana JE, Harrington T, Cano M, Lewis P, Mba-Jonas A, Rongxia L, et al. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009\u20132015. Vaccine. 2018;36:1781\u20138.","journal-title":"Vaccine"},{"key":"930_CR24","doi-asserted-by":"publisher","first-page":"e61825","DOI":"10.1371\/journal.pone.0061825","volume":"8","author":"E Draper","year":"2013","unstructured":"Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, et al. A randomized, observer-blinded immunogenicity trial of Cervarix\u00ae and Gardasil\u00ae human papillomavirus vaccines in 12\u201315-year-old girls. PLoS One. 2013;8:e61825.","journal-title":"PLoS One"},{"key":"930_CR25","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1016\/j.vaccine.2015.03.098","volume":"33","author":"LS Brinth","year":"2015","unstructured":"Brinth LS, Pors K, Theibel AC, Mehlsen J. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine. 2015;33:2602\u20135.","journal-title":"Vaccine."},{"key":"930_CR26","unstructured":"Prescribing Information of Gardasil and Cervarix 2019. https:\/\/nedrug.mfds.go.kr\/index. Accessed Nov 22, 2019."},{"key":"930_CR27","doi-asserted-by":"crossref","unstructured":"Gar\u00e7on N, Van Mechelen M, Wettendorff M. Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt. In: Schijns VEJC, O\u2019Hagan DT, editors. Immunopotentiators in modern vaccines. Academic Press; 2006. pp. 161\u201377.","DOI":"10.1016\/B978-012088403-2\/50011-3"},{"key":"930_CR28","unstructured":"Korea Institute of Drug Safety and Risk Management. User guide: Korea Institute of Drug Safety and Risk Management-Korea adverse event reporting system database (KIDS-KD). Ver. 5. 2018."},{"key":"930_CR29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905\u20138.","journal-title":"Br J Clin Pharmacol."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00930-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00930-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00930-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T14:20:58Z","timestamp":1659104458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00930-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,30]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["930"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00930-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2020,5,30]]},"assertion":[{"value":"30 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This research was supported by the Government-wide R&D Fund project for infectious disease research through the Government-wide R&D Fund for Infectious Disease Research (GFID) funded by the Korea Health Industry Development Institute (No. HG18C0068).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest directly relevant to the content of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Sungkyunkwan University located in Seoul, Korea (Approval Number: 2018-12-013). All procedures performed for studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments, or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}